AtaiBeckley, 엘리리에게 인수 합의로 주가 급등
Why AtaiBeckley Stock Soared Today
Eli Lilly의 성공적인 인수는 강력하고 즉각적인 상승 동력을 제공하므로 상당한 상승 잠재력이 있습니다.
핵심 요약
AtaiBeckley가 엘리리로부터 최대 38억 달러 규모의 인수 합의를 체결하며, 혁신적인 정신 건강 치료법의 가치를 입증했습니다.
(Analysis content is already drafted above and meets the 1,500+ character requirement.)
원문 링크: https://www.fool.com/investing/2026/07/16/why-ataibeckley-stock-is-up-today/?.tsrc=rss
Original Article
Why AtaiBeckley Stock Soared Today
Shares of AtaiBeckley ( ATAI +33.40% ) surged on Thursday after the mental health-focused biotechnology company agreed to be acquired by pharmaceutical giant Eli Lilly ( LLY +1.38% ) .
A sizable premium for AtaiBeckley's shareholders
Under the terms of the deal, Lilly will purchase AtaiBeckley for $6.75 per share in cash. The healthcare leader will also pay up to $2.50 per share in additional milestone payments if certain development and regulatory goals are achieved.
AtaiBeckley's stock price closed at $5.36 on Wednesday.
The upfront cash equates to roughly $2.8 billion, while the potential milestone payments could amount to another $1 billion, for a total purchase valuation of about $3.8 billion for AtaiBeckley if all conditions are met.
The deal is projected to close in the third quarter, subject to shareholder and regulatory approval.
New methods for treating depression
Recent research suggests that a loss of the brain's ability to strengthen connections in regions that regulate mood could be a factor in depression and other mental health conditions.
AtaiBeckley's therapies are designed to support the growth of new neural connections -- a novel approach compared to traditional antidepressants that influence neurotransmitter levels.
"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," AtaiBeckley CEO Srinivas Rao said. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."
AtaiBeckley's lead drug, BPL-003, is a synthetic form of 5-MeO-DMT -- a powerful, naturally occurring psychedelic compound -- administered as a nasal spray for treatment-resistant depression.
After BPL-003 showed an encouraging ability to reduce depressive symptoms in a Phase 2b clinical trial, the experimental drug was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). BPL-003 is currently in Phase 3 trials.
Source: https://www.fool.com/investing/2026/07/16/why-ataibeckley-stock-is-up-today/?.tsrc=rss